Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin?

Dermatologic Surgery

Volumn 33, Issue 12, 2007, Pages 1419-1429

  Smith, Kathleen ^a   Hamza, Sate ^b   Germain, Marguerite ^c   Skelton, Henry ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; IMIQUIMOD; PROTEIN P53; PROTEIN P63; STEM CELL FACTOR RECEPTOR; CYCLINE; CYTOKINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR AP 1;

ACTINIC KERATOSIS; ADULT; ARTICLE; BASAL CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELASTOSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; STAINING; ULTRAVIOLET RADIATION; BASAL CELL CARCINOMA; CUTANEOUS PARAMETERS; HISTOPATHOLOGY; KERATINIZATION; NOTE; RADIATION INJURY; SKIN CANCER; SKIN INJURY; VERRUCA VULGARIS;

EID: 36749077604     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2007.33311.x     Document Type: Article

References (47)

1. Smith KJ, Hamza S, Skelton H. The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin Pharmacother 2003 4 : 1105 19.
2. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006 18 : 3 9.
3. McInturff JE, Modlin RL, Kim J. The role of Toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 2005 125 : 1 8.
4. Schon MP, Schon M. Immune modulation and apoptosis induction. two sides of the antitumoral activity of imiquimod. Apoptosis 2004 9 : 291 8.
5. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004 51 : 547 55.
6. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004 140 : 1542.
7. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002 47 : 571 7.
8. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-κB pathway. Trends Immunol 2005 26 : 469 76.
9. Smith KJ, Germain M, Yeager J, Skelton H. Topical 5% imiquimod for the therapy of actinic chelitis. J Am Acad Dermatol 2002 47 : 497 501.
10. Liebermann DA, Hoffman B. Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia 2002 16 : 527 41.
11. Barnes BJ, Richards J, Mancl M, et al. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004 279 : 45194 207.
12. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998 282 : 1484 7.
13. Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associated genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol 2005 11 : 6941 7.
14. Lillard-Wetherell K, Machwe A, Langland GT, et al. Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2. Hum Mol Genet 2004 13 : 1919 32.
15. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005 175 : 1636 42.
16. Barnes BJ, Kellum MJ, Pinder KE, et al. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003 63 : 6424 31.
17. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002 22 : 5721 40.
18. Beinke S, Ley SC. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 2004 382 : 393 409.
19. Schwarz A, Maeda A, Kernebeck K, et al. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med 2005 201 : 173 9.
20. Betelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. J Exp Med 2005 201 : 169 71.
21. Prost S, Bellamy COC, Cunningham DS, Harrison DJ. Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes. FASEB J 1998 12 : 181 8.
22. Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res 2005 57 : 91 106.
23. de Gruijl FR. p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects. Exp Dermatol 2002 11 (Suppl 1) : 37 9.
24. Hattori H, Kawashima M, Ichikawa Y, Imokawa G. The epidermal stem cell factor is over-expressed in lentigo senilis. implications for the mechanism of hyperpigmentation. J Invest Deramtol 2004 122 : 1256 65.
25. Imokawa G. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res 2004 17 : 96 110.
26. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004 2 : 371 86.
27. Park HR, Min SK, Cho HD, et al. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J Cutan Pathol 2004 31 : 544 9.
28. Li N, Li H, Cherukuri P, et al. TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53. Oncogene 2006 25 : 2349 59.
29. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003 116 : 3051 60.
30. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991 5 : 3071 7.
31. Yamaguchi Y, Hearing VJ, Itami S, et al. Mesenchymal-epithelial interactions in the skin: aiming for site-specific tissue regeneration. J Dermatol Sci 2005 40 : 1 9.
32. Goukassian DA, Helms E, van Steeg H, et al. Topical DNA oligonucleotide therapy reduces UV-induced mutations and photocarcinogenesis in hairless mice. Proc Natl Acad Sci U S A 2004 101 : 3933 8.
33. Goukassian DA, Bagheri S, el-Keeb L, et al. DNA oligonucleotide treatment corrects the age-associated decline in DNA repair capacity. FASEB J 2002 16 : 754 60.
34. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage response. Proc Natl Acad Sci U S A 2005 102 : 8222 7.
35. Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatolog Treat 2002 13 : 123 7.
36. Micali G, Lacarrubba F, Nasca MR, et al. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol 2003 28 (Suppl 1) : 19 23.
37. Micali M, Nasca MR, Musumeci ML. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream. Int J Tissue React 2005 27 : 111 4.
38. Micali G, Nasca MR, De Pasquale R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol 2006 55 : 901 3.
39. Micali G, Nasca MR, Tedeschi A. Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin Exp Dermatol 2003 28 (Suppl 1) : 4 6.
40. Micali G, Dall'Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat 2003 14 : 233 6.
41. Thatcher TH, Luzina I, Fishelevich R, et al. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol 2006 126 : 821 31.
42. Metcalf S, Crowson AN, Naylor M, et al. Imiquimod as an antiaging agent. J Am Acad Dermatol 2007 56 : 422 5.
43. Prado A, Andrades P, Benitez S. Preliminary results after face peels using Aldara cream 5% (imiquimod). Plast Reconstr Surg 2005 116 : 1563 8.
44. Schiller M, Metze D, Luger TA, et al. Immune response modifiers-mode of action. Exp Dermatol 2006 15 : 331 41.
45. Berman B, Frankel S, Villa AM, et al. Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. Dermatol Surg 2005 31 : 1399 403.
46. Lain EL, Carrington PR. Imiquimod treatment of exuberant granulation tissue in a nonhealing diabetic ulcer. Arch Dermatol 2005 141 : 1368 70.
47. Namazi H. Imiquimod: a potential weapon against Dupuytren contracture. Med Hypotheses 2006 66 : 991 2.